Gilead Sciences annual operating expenses
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Operating Expenses Growth & History (GILD)
Gilead Sciences's operating expenses was $13.19B for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $13.19B | −$7.65B | −36.73% |
| 2024 | 2024-12-31 | $20.84B | $7.83B | +60.16% |
| 2023 | 2023-12-31 | $13.01B | −$1.28B | −8.96% |
| 2022 | 2022-12-31 | $14.29B | $3.51B | +32.52% |
| 2021 | 2021-12-31 | $10.79B | −$5.26B | −32.78% |
| 2020 | 2020-12-31 | $16.05B | $2.56B | +18.97% |
| 2019 | 2019-12-31 | $13.49B | $4.41B | +48.63% |
| 2018 | 2018-12-31 | $9.07B | $1.46B | +19.21% |
| 2017 | 2017-12-31 | $7.61B | −$884.0M | −10.40% |
| 2016 | 2016-12-31 | $8.50B | $2.06B | +31.93% |
| 2015 | 2015-12-31 | $6.44B | $603.0M | +10.33% |
| 2014 | 2014-12-31 | $5.84B | $2.02B | +52.84% |
| 2013 | 2013-12-31 | $3.82B | $597.5M | +18.55% |
| 2012 | 2012-12-31 | $3.22B | $750.4M | +30.37% |
| 2011 | 2011-12-31 | $2.47B | $353.8M | +16.71% |
| 2010 | 2010-12-31 | $2.12B | $230.7M | +12.23% |
| 2009 | 2009-12-31 | $1.89B | $356.6M | +23.31% |
| 2008 | 2008-12-31 | $1.53B | $233.2M | +17.98% |
| 2007 | 2007-12-31 | $1.30B | — | — |
Gilead Sciences quarterly operating expenses
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.62B | $13.51B | +434.86% |
| Q1 2026 | 2026-03-31 | $2.93B | $39.0M | +1.35% |
| Q4 2025 | 2025-12-31 | $4.32B | $781.0M | +22.09% |
| Q3 2025 | 2025-09-30 | $2.87B | −$2.21B | −43.48% |
| Q2 2025 | 2025-06-30 | $3.11B | $341.0M | +12.33% |
| Q1 2025 | 2025-03-31 | $2.89B | −$6.57B | −69.44% |
| Q4 2024 | 2024-12-31 | $3.54B | $124.0M | +3.63% |
| Q3 2024 | 2024-09-30 | $5.08B | $2.22B | +77.54% |
| Q2 2024 | 2024-06-30 | $2.77B | −$726.0M | −20.79% |
| Q1 2024 | 2024-03-31 | $9.46B | $6.21B | +191.31% |
| Q4 2023 | 2023-12-31 | $3.41B | −$314.0M | −8.43% |
| Q3 2023 | 2023-09-30 | $2.86B | $53.0M | +1.89% |
| Q2 2023 | 2023-06-30 | $3.49B | $703.0M | +25.21% |
| Q1 2023 | 2023-03-31 | $3.25B | −$1.72B | −34.67% |
| Q4 2022 | 2022-12-31 | $3.73B | $49.0M | +1.33% |
| Q3 2022 | 2022-09-30 | $2.81B | $454.0M | +19.27% |
| Q2 2022 | 2022-06-30 | $2.79B | $208.0M | +8.06% |
| Q1 2022 | 2022-03-31 | $4.97B | $2.80B | +128.78% |
| Q4 2021 | 2021-12-31 | $3.68B | $64.0M | +1.77% |
| Q3 2021 | 2021-09-30 | $2.36B | −$995.0M | −29.69% |
| Q2 2021 | 2021-06-30 | $2.58B | −$4.41B | −63.05% |
| Q1 2021 | 2021-03-31 | $2.17B | $76.0M | +3.63% |
| Q4 2020 | 2020-12-31 | $3.61B | $263.0M | +7.85% |
| Q3 2020 | 2020-09-30 | $3.35B | −$2.60B | −43.72% |
| Q2 2020 | 2020-06-30 | $6.99B | $4.81B | +220.90% |
| Q1 2020 | 2020-03-31 | $2.10B | $90.0M | +4.49% |
| Q4 2019 | 2019-12-31 | $3.35B | −$67.0M | −1.96% |
| Q3 2019 | 2019-09-30 | $5.95B | $4.21B | +241.01% |
| Q2 2019 | 2019-06-30 | $2.18B | $113.0M | +5.47% |
| Q1 2019 | 2019-03-31 | $2.01B | $159.0M | +8.61% |
| Q4 2018 | 2018-12-31 | $3.42B | $682.0M | +24.94% |
| Q3 2018 | 2018-09-30 | $1.75B | $188.0M | +12.07% |
| Q2 2018 | 2018-06-30 | $2.06B | $398.0M | +23.89% |
| Q1 2018 | 2018-03-31 | $1.85B | $194.0M | +11.74% |
| Q4 2017 | 2017-12-31 | $2.73B | $202.0M | +7.97% |
| Q3 2017 | 2017-09-30 | $1.56B | −$319.0M | −17.00% |
| Q2 2017 | 2017-06-30 | $1.67B | −$583.0M | −25.92% |
| Q1 2017 | 2017-03-31 | $1.65B | −$184.0M | −10.02% |
| Q4 2016 | 2016-12-31 | $2.53B | $319.0M | +14.41% |
| Q3 2016 | 2016-09-30 | $1.88B | $315.0M | +20.17% |
| Q2 2016 | 2016-06-30 | $2.25B | $737.0M | +48.74% |
| Q1 2016 | 2016-03-31 | $1.84B | $685.0M | +59.46% |
| Q4 2015 | 2015-12-31 | $2.21B | −$31.0M | −1.38% |
| Q3 2015 | 2015-09-30 | $1.56B | $61.0M | +4.06% |
| Q2 2015 | 2015-06-30 | $1.51B | $436.0M | +40.52% |
| Q1 2015 | 2015-03-31 | $1.15B | $137.0M | +13.50% |
| Q4 2014 | 2014-12-31 | $2.25B | $859.0M | +61.98% |
| Q3 2014 | 2014-09-30 | $1.50B | $620.9M | +70.54% |
| Q2 2014 | 2014-06-30 | $1.08B | $256.8M | +31.35% |
| Q1 2014 | 2014-03-31 | $1.01B | $281.3M | +38.33% |
| Q4 2013 | 2013-12-31 | $1.39B | $353.3M | +34.21% |
| Q3 2013 | 2013-09-30 | $880.1M | $163.3M | +22.79% |
| Q2 2013 | 2013-06-30 | $819.2M | $174.4M | +27.04% |
| Q1 2013 | 2013-03-31 | $733.7M | −$93.5M | −11.30% |
| Q4 2012 | 2012-12-31 | $1.03B | $68.3M | +7.08% |
| Q3 2012 | 2012-09-30 | $716.8M | $186.6M | +35.20% |
| Q2 2012 | 2012-06-30 | $644.8M | $155.8M | +31.86% |
| Q1 2012 | 2012-03-31 | $827.2M | $339.7M | +69.69% |
| Q4 2011 | 2011-12-31 | $964.4M | −$199.6M | −17.15% |
| Q3 2011 | 2011-09-30 | $530.2M | $121.3M | +29.66% |
| Q2 2011 | 2011-06-30 | $489.0M | $131.1M | +36.63% |
| Q1 2011 | 2011-03-31 | $487.5M | $301.0M | +161.40% |
| Q4 2010 | 2010-12-31 | $1.16B | $356.4M | +44.13% |
| Q3 2010 | 2010-09-30 | $408.9M | $64.1M | +18.57% |
| Q2 2010 | 2010-06-30 | $357.9M | −$66.4M | −15.64% |
| Q1 2010 | 2010-03-31 | $186.5M | −$123.4M | −39.81% |
| Q4 2009 | 2009-12-31 | $807.6M | — | — |
| Q3 2009 | 2009-09-30 | $344.8M | −$32.4M | −8.59% |
| Q2 2009 | 2009-06-30 | $424.3M | $17.3M | +4.26% |
| Q1 2009 | 2009-03-31 | $309.9M | — | — |
| Q3 2008 | 2008-09-30 | $377.3M | — | — |
| Q2 2008 | 2008-06-30 | $406.9M | — | — |
Gilead Sciences operating expenses trends
Over the last five fiscal years, Gilead Sciences's operating expenses decreased from $16.05B to $13.19B, a change of −$2.86B. The latest reported quarter, Q2 2026, shows $16.62B.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
